You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • AB0274 Impact of Baseline Anti-Cyclic Citrullinated Peptide 2 Antibody Titre on Efficacy Outcomes Following Treatment with Subcutaneous Abatacept or Adalimumab: 2-Year Results from the Ample Trial

Citation Tools

Article menu
Download PDFPDF
Abstracts Accepted for Publication
Rheumatoid arthritis - prognosis, predictors and outcome
AB0274 Impact of Baseline Anti-Cyclic Citrullinated Peptide 2 Antibody Titre on Efficacy Outcomes Following Treatment with Subcutaneous Abatacept or Adalimumab: 2-Year Results from the Ample Trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Sokolove J, Schiff M, Fleischmann R, et al
AB0274 Impact of Baseline Anti-Cyclic Citrullinated Peptide 2 Antibody Titre on Efficacy Outcomes Following Treatment with Subcutaneous Abatacept or Adalimumab: 2-Year Results from the Ample Trial
Annals of the Rheumatic Diseases 2015;74:983-984.